Skip to main content
Clinical Trials/JPRN-UMIN000043917
JPRN-UMIN000043917
Recruiting
未知

Observational study investigating the efficacy and safety of fulvestrant + CDK4 / 6 inhibitor as a primary endocrine therapy for hormone receptor-positive, HER2-negative advanced/metastatic breast cancer - Observational study investigating the efficacy and safety of fulvestrant + CDK4 / 6 inhibitor as a primary endocrine therapy for hormone receptor-positive, HER2-negative advanced/metastatic breast cancer

Breast Surgery, Yokkaichi Municipal Hospital0 sites30 target enrollmentApril 14, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Breast Surgery, Yokkaichi Municipal Hospital
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 14, 2021
End Date
December 31, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Breast Surgery, Yokkaichi Municipal Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Recurrence during postoperative hormone therapy or within 1 year from completion of treatment 2\) Known uncontrolled or symptomatic central nervous system metastases 3\) Patients with advanced symptomatic visceral spread that are at risk of life threatening complication in the short term 4\) Prior endocrine therapy for advanced/metastatic breast cancer 5\) Known interstitial lung disease on imaging 6\) Known uncontrolled infection 7\) Current pregnancy and lactation or possibility of pregnancy 8\) Known drug allergy to any of study drugs 9\) Assessment by investigator that subject unable to comply with protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials